

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
10 May 2024 (10.05.2024)



(10) International Publication Number
WO 2024/097697 A3

(51) International Patent Classification:

C12N 5/074 (2010.01) C12N 5/077 (2010.01)
C12N 5/0735 (2010.01) C12N 15/113 (2010.01)
A61P 37/06 (2006.01) C12N 15/79 (2006.01)

(21) International Application Number:

PCT/US2023/078272

(22) International Filing Date:

31 October 2023 (31.10.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/US2022/079017
01 November 2022 (01.11.2022) US
63/491,032 17 March 2023 (17.03.2023) US
63/493,880 03 April 2023 (03.04.2023) US
63/507,793 13 June 2023 (13.06.2023) US

(71) Applicant: **VERTEX PHARMACEUTICALS INCORPORATED** [US/US]; 50 Northern Avenue, Boston, Massachusetts 02210 (US).

(72) Inventors: **COOKE, Michael**; c/o Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, Massachusetts 02210 (US). **CONWAY, Michael**; c/o Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, Massachusetts 02210 (US). **KISSLER, Stephan**; c/o Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, Massachusetts 02210 (US). **CAREY, Bryce**; c/o Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, Massachusetts 02210 (US). **RAJ, Suyash**; c/o Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, Massachusetts 02210 (US).

(74) Agent: **WALSH, Daniel, A.**; Klarquist Sparkman LLP, One World Trade Center, Suite 1600, 121 SW Salmon Street, Portland, Oregon 97204 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:

13 June 2024 (13.06.2024)

(54) Title: GENETICALLY ENGINEERED CELLS

(57) Abstract: Disclosed herein are compositions and methods related to genetically engineered mammalian cells comprising adjusted expression of select genes. The genetically engineered mammalian cells described herein advantageously possess improved survivability.

WO 2024/097697 A3